{Reference Type}: Journal Article
{Title}: Recent developments of hydroxamic acid hybrids as potential anti-breast cancer agents.
{Author}: Cao X;Gong Y;
{Journal}: Future Med Chem
{Volume}: 16
{Issue}: 5
{Year}: 2024 03 31
{Factor}: 4.767
{DOI}: 10.4155/fmc-2023-0284
{Abstract}: Histone deacetylase inhibitors not only possess favorable effects on modulating tumor microenvironment and host immune cells but also can reactivate the genes silenced due to deacetylation and chromatin condensation. Hydroxamic acid hybrids as promising histone deacetylase inhibitors have the potential to address drug resistance and reduce severe side effects associated with a single drug molecule due to their capacity to simultaneously modulate multiple targets in cancer cells. Accordingly, rational design of hydroxamic acid hybrids may provide valuable therapeutic interventions for the treatment of breast cancer. This review aimed to provide insights into the in vitro and in vivo anti-breast cancer therapeutic potential of hydroxamic acid hybrids, together with their mechanisms of action and structure-activity relationships, covering articles published from 2020 to the present.